Actively Recruiting

Age: 19Years +
All Genders
NCT06979219

Streamlining Radioembolization for Small HCC

Led by Seoul National University Hospital · Updated on 2026-04-09

146

Participants Needed

4

Research Sites

237 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In patients who has no sign suggesting high lung shunt fraction (TIPS, hepatic vein invasion, hepatic vein enhancement on arterial phase, dysmorphic intratumoral vessel, tumor size \< 5cm), radioembolization is performed without MAA scan with SIR-Spheres. This prospective registry will prove that the selection criteria is accurate and streamlining radioembolization is feasible and safe.

CONDITIONS

Official Title

Streamlining Radioembolization for Small HCC

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged >18 years
  • Diagnosed with hepatocellular carcinoma histologically and/or radiologically (LI-RADS 4 or 5)
  • Hepatocellular carcinoma 5 cm or smaller
  • Tumor number is 3 or smaller
  • Dysmorphic intratumoral vessel is absent or smaller than 3 mm
  • Child-Pugh class A
  • ECOG performance status 0 or 1
  • Laboratory values must meet: Leukocytes ≥ 1,000/µL and ≤ 20,000/µL, Hemoglobin ≥ 6.0 g/dL (transfusion allowed), Total bilirubin ≤ 2.0 mg/dL, Platelet count ≥ 40,000/µL, INR ≤ 2.0 if not on anticoagulants, AST ≤ 800 IU/L, ALT ≤ 800 IU/L, Creatinine ≤ 2.5 mg/dL (no upper limit if on hemodialysis)
  • Life expectancy greater than 3 months
  • Able to understand the clinical trial and provide written consent
  • Nonpregnant women of childbearing potential
Not Eligible

You will not qualify if you...

  • Hepatic vein invasion seen on CT or MRI
  • Marked enhancement of portal vein or hepatic vein on arterial phase of CT or MRI
  • Dysmorphic intratumoral vessel 3 mm or larger
  • Presence of transjugular intrahepatic portosystemic shunt (TIPS)
  • Bilioenteric anastomosis or biliary stent
  • Centrilobular emphysema or interstitial lung disease
  • Main portal vein invasion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

National Cancer Center

Goyang, South Korea

Actively Recruiting

2

Samsung Medical Center

Seoul, South Korea

Not Yet Recruiting

3

Seoul National University Hospital

Seoul, South Korea

Actively Recruiting

4

Severance hospital

Seoul, South Korea

Not Yet Recruiting

Loading map...

Research Team

H

Hyo-Cheol Kim, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Streamlining Radioembolization for Small HCC | DecenTrialz